Keros Therapeutics’ (KROS) “Overweight” Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald reiterated their overweight rating on shares of Keros Therapeutics (NASDAQ:KROS) in a report published on Friday,Benzinga reports.

Other equities research analysts have also issued reports about the company. HC Wainwright reaffirmed a “buy” rating and set a $100.00 target price on shares of Keros Therapeutics in a research report on Thursday, November 7th. Wedbush restated an “outperform” rating and issued a $84.00 target price on shares of Keros Therapeutics in a report on Thursday, November 7th. Jefferies Financial Group initiated coverage on Keros Therapeutics in a report on Tuesday, November 5th. They set a “buy” rating on the stock. Guggenheim assumed coverage on Keros Therapeutics in a research note on Monday, September 23rd. They issued a “buy” rating and a $96.00 price objective for the company. Finally, Bank of America decreased their price objective on Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating for the company in a research report on Thursday, September 12th. Twelve investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $88.89.

Keros Therapeutics Stock Up 1.2 %

Shares of NASDAQ KROS opened at $56.58 on Friday. Keros Therapeutics has a fifty-two week low of $27.31 and a fifty-two week high of $73.00. The stock has a market cap of $2.29 billion, a P/E ratio of -10.86 and a beta of 1.23. The firm’s 50-day simple moving average is $59.32 and its 200 day simple moving average is $52.16.

Keros Therapeutics (NASDAQ:KROS) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($1.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.28) by ($0.13). Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The firm had revenue of $0.39 million for the quarter. During the same quarter in the previous year, the business posted ($1.33) EPS. The business’s revenue for the quarter was up 4750.0% compared to the same quarter last year. On average, sell-side analysts anticipate that Keros Therapeutics will post -5.28 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Keros Therapeutics

Several institutional investors have recently made changes to their positions in KROS. KBC Group NV lifted its holdings in Keros Therapeutics by 52.0% in the 3rd quarter. KBC Group NV now owns 1,263 shares of the company’s stock worth $73,000 after purchasing an additional 432 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in Keros Therapeutics by 26.0% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock worth $77,000 after purchasing an additional 280 shares in the last quarter. Values First Advisors Inc. acquired a new stake in Keros Therapeutics in the 3rd quarter valued at about $89,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Keros Therapeutics in the second quarter valued at approximately $128,000. Finally, Ameritas Investment Partners Inc. increased its stake in shares of Keros Therapeutics by 14.5% in the 1st quarter. Ameritas Investment Partners Inc. now owns 2,560 shares of the company’s stock valued at $169,000 after buying an additional 324 shares during the period. 71.56% of the stock is currently owned by institutional investors and hedge funds.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.